Skip to main content
Rafael Gonzalez-Amado, MD, Hematology, South San Francisco, CA

Rafael Gonzalez-Amado MD

Hematology•South San Francisco, CA

Physician

Join to View Full Profile

  • 210 E Grand AveSouth San Francisco, CA 94080

  • Phone+1 610-551-2740

  • Fax+1 310-301-8751

Join Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
Join DoximityAlready have an account?

Summary

  • Dr. Rafael Gonzalez-Amado, MD is a hematologist in South San Francisco, California. He is currently licensed to practice medicine in California.

Education & Training

  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1992 - 1995
  • University of Illinois College of Medicine at Chicago
    University of Illinois College of Medicine at ChicagoResidency, Internal Medicine, 1989 - 1992
  • Universidad de Cadiz Faculty of Medicine
    Universidad de Cadiz Faculty of MedicineClass of 1987

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1992 - 2026
  • CA State Medical License
    CA State Medical License 1992 - 2026

Publications & Presentations

PubMed

Press Mentions

  • Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)
    Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)January 23rd, 2025
  • Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer
    Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical CancerJanuary 15th, 2025
  • ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer
    ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung CancerOctober 24th, 2024

Dr. Rafael Gonzalez-Amado, Dr. Rafael Gonzalez-Amado, MD, Dr. R Gonzalez-Amado